Cannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041 ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]
Lire la suiteCannabis thérapeutique : «Tous les voyants sont au vert» Par Charles Delouche — 29 mai 2019 à 18:50 Libération Alors que l’Agence nationale du médicament doit rendre son projet d'expérimentation du cannabis thérapeutique fin juin, le Sénat a débattu du sujet ce mercredi à l’initiative d’Esther Benbassa, sénatrice EE-LV de Paris. Battre le fer tant qu’il est chaud. C’est l’idée qui animait le débat sans vote qui s’est déroulé ce mercredi au Sénat autour du cannabis thérapeutique à l'initiative d'Esther Benbassa, sénatrice Europe Ecologie-les Verts (EE-LV) de Paris. La veille, une conférence de presse était organisée aux côtés de [...]
Lire la suiteCannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder Tristan Dale, Jenny Downs, Heather Olson, Ann Marie Bergin, Stephanie Smith and Helen Leonard Epilepsy Research, 2019 DOI: https://doi.org/doi:10.1016/j.eplepsyres.2019.02.001 Abstract Severe paediatric epilepsies such as CDKL5 Deficiency Disorder (CDD) are extremely debilitating, largely due to the early-onset and refractory nature of the seizures. Existing treatment options are often ineffective and associated with a host of adverse effects, causing those that are affected to seek alternative treatments. Cannabis based products have attracted significant attention over recent years, primarily driven by reports of miraculous cures and a renewed public preference for ‘natural’ therapies, [...]
Lire la suiteExtractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067 Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and processing [...]
Lire la suiteCannabis Chemovar Nomenclature Misrepresents Chemical and Genetic Diversity; Survey of Variations in Chemical Profiles and Genetic Markers in Nevada Medical Cannabis Samples Ulrich Reimann-Philipp, Mark Speck, Cindy Orser, Steve Johnson, Aaron Hilyard, Helen Turner, Alexander J. Stokes, and Andrea L. Small-Howard Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0063 Abstract Introduction : Medical cannabis patients receive clinical benefits from the secondary metabolites of the plant, which contain a variety of cannabinoids and terpenoids in combinations that can be used to classify the chemovars. State-regulated medical cannabis programs rely on breeder-reported ‘‘strain’’ names both within diversion control systems and to [...]
Lire la suitePotency Analysis of Medical Marijuana Products from New York State Lingyun Li, Bryan C. Duffy, Lorie A. Durocher, Mark A. Dittmar, Robert A. Acosta, Emily R. Delaney, Lei Li, Kenneth M. Aldous and David C. Spink Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0037 Abstract Introduction : In the United States, medicalmarijuana programs have been established in 29 states and the District of Columbia. In 2014, New York State (NYS) approved medical marijuana legislation, and its program became fully operational in January of 2016. Products manufactured under the auspices of the program may be used by certified patients in [...]
Lire la suiteLe Cannabidiol, l’autre canabinoïde présent dans le cannabis : une piste thérapeutique prometteuse? Traiter la dépendance avec du cannabidiol ? Si peu d’études ont pour l’heure été menées chez l’Homme, l’idée fait son chemin... et inspire les instigateurs d’une étude-pilote «CANNAVAP». Grégoire Cleirec et Pierre Poloméni Publié le 20 Mai 2019 par : Revue SWAPS n°90, "Du Cannabis Thérapeutique à la Régulation". http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891 L’Agence nationale de sécurité du médicament (ANSM) a annoncé récemment la création d’un comité scientifique spécialisé sur «l’évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France». Une façon de combler notre retard. À [...]
Lire la suitePharmacokinetics and Tolerability of Δ9-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of Δ9-THC Mahmoud A. ElSohly, Waseem Gul, Larry A. Walker Medical Cannabis and Cannabinoids, 2018, 1, 44–53 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489037 Abstract The objectives of this study were: (1) to assess the safety, tolerability, and pharmacokinetics of ascending doses of Δ9- tetrahydrocannabinol-hemisuccinate (THC-HS) after rectal administration as suppositories in male volunteers; and (2) to compare the pharmacokinetics of oral administration of Δ9-tetrahydrocannabinol (Δ9-THC) with an equivalent amount of Δ9-THC delivered as THC-HS via the suppository formulation. In support of the pharmacokinetic evaluations, [...]
Lire la suiteMedical Cannabis and Cannabinoids : An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? Magdalena Grill, Carina Hasenoehrl, Martin Storr, Rudolf Schicho Medical Cannabis and Cannabinoids, 2018, 1, 28–35 © 2018 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca DOI: 10.1159/000489036 Abstract : In the past few years, we have witnessed a surge of new reports dealing with the role of cannabinoids, synthetic as well as herbal, in the mechanisms of inflammation and carcinogenesis. However, despite the wealth of in vitro data and anecdotal reports, evidence that cannabinoids could act as beneficial drugs in inflammatory bowel disease (IBD) or in [...]
Lire la suiteCannabis and Pain : A Clinical Review Kevin P. Hill, Matthew D. Palastro, Brian Johnson, and Joseph W. Ditre Cannabis and Cannabinoid Research, Volume 2.1, 2017 DOI: 10.1089/can.2017.0017 Abstract Introduction : Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain. There is a theoretical rationale for cannabis' efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence [...]
Lire la suite